Healthcare Plans. Scored on the same transparent model behind the daily rankings.
★
ELV
Elevance Health, Inc. · Healthcare Plans
45.1Score
$412.70Oct 9 close$89.5B
1Y Target$451.48Analyst consensus · 21 analysts
5Y Target$661.01Compound horizon
10Y Target$980.56Long-dated conviction
FCF$6.3bTTM · 06/26B+
FCF $6.3b — strong cash profile, above most peers · Trailing twelve months to 06/26 (operating cash flow − capex).
Rev+12.6%FY YoYB+
Revenue +12.6% — above sector median, healthy trajectory · Computed from the last two annual revenue figures (FY YoY).
D/E0.69C+
D/E 0.69 — above the Healthcare debt median (≈75th pctile)
P/E18.3xA-
P/E 18.3 — cheaper than most Healthcare peers (≈25th pctile)
PEG*——
PEG n/a — analysts expect next year's earnings to be no higher than last year's
* PEG n/a — analysts expect next year's earnings to be no higher than last year's
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 45.1
Quality54.6
Growth64.9
Value25.8
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeNear 52-week high
5% off the 12-month high
vs DCF fair value36% belowest. fair value ~$644
What the price assumes: free cash flow shrinking about 3% next year, then recovering toward 4% a year by year ten — vs a starting rate of ~10% our model takes as the middle of three readings — analyst estimates, last year's revenue growth, and the company's own multi-year record.
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Healthcare Plans · market cap $89.5b. 5% off the 52-week high of $436.24. Revenue growing +13%, comfortably above the S&P median. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $451.48 (implying +9% upside).
Moat
ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 127% of net income — earnings translate cleanly into cash. $89.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Net margin 2.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $451.48 (21-analyst consensus) — fundamentals + valuation re-rating. 5 yr $661.01 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $980.56 if current growth sustains into durable earnings power.
ELV vs the Top Picks average
Pillar
ELV
Book avg
Diff
Quality
55
83
-28
Growth
65
89
-24
Value
26
76
-50
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · ELV
Trend
-19.7 over 82 daily scores
From 64.8 (Jun 22) → 45.1 (now)
One point per daily run; read From → To for the actual range.
ELV at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
-0.1%
90-day change
+0.9%
Forward EPS estimate
$29.59
Over the last 90 days, what analysts expect ELV to earn is essentially unchanged. The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · ELV
$
%
%
Shares to buy
4
Position size
$1,651
3.3% of portfolio
Stop price
$309.52
25% below $412.70
$ at risk if stopped
$412.70
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Elevance Health, Inc. (ELV): score, valuation & FAQ
Elevance Health, Inc. (ELV) is a Healthcare Plans company that scores 45.1 out of 100 on the Bull Rankings quality-growth model — a below-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-), FCF (B+) and Rev (B+). On valuation, ELV sits about 36% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow shrinking about 3% next year, then recovering toward 4% a year by year ten.
Is ELV a good stock to buy?
Bull Rankings scores ELV 45.1 out of 100 on its quality-growth model, which is a below-average reading. That is driven by P/E (A-), FCF (B+) and Rev (B+). A score is a quantitative screen of Elevance Health, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ELV score 45.1 on Bull Rankings?
The score leans on growth at 64.9 out of 100, with value the weakest pillar at 25.8 — the three combine geometrically, so a weak one cannot be papered over by a strong one. ELV earns its highest marks on P/E (A-), FCF (B+) and Rev (B+). Each signal is graded against sector-aware thresholds rather than one absolute bar, so ELV is measured against Healthcare Plans peers, not against the market as a whole.
Is ELV overvalued or undervalued?
Based on $412.70, ELV sits about 36% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow shrinking about 3% next year, then recovering toward 4% a year by year ten. It trades at an 18.3x P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ELV?
Net margin 2.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.